These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 7142182)

  • 81. Binding kinetics of thrombin and antithrombin III with immobilized heparin using a spacer.
    Byun Y; Jacobs HA; Kim SW
    ASAIO J; 1992; 38(3):M649-53. PubMed ID: 1457941
    [TBL] [Abstract][Full Text] [Related]  

  • 82. The rate of the thrombin/antithrombin III reaction is determined with their molar ratio rather than their absolute concentrations.
    Oshima G; Nagasawa K
    Thromb Res; 1987 Apr; 46(2):263-70. PubMed ID: 3603424
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Conformational changes accompanying the binding of antithrombin III to thrombin.
    Villanueva G; Danishefsky I
    Biochemistry; 1979 Mar; 18(5):810-7. PubMed ID: 420817
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Effect of heparin on the glia-derived-nexin-thrombin interaction.
    Wallace A; Rovelli G; Hofsteenge J; Stone SR
    Biochem J; 1989 Jan; 257(1):191-6. PubMed ID: 2920011
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Mechanism of heparin action.
    Jackson CM
    Baillieres Clin Haematol; 1990 Jul; 3(3):483-504. PubMed ID: 2176902
    [TBL] [Abstract][Full Text] [Related]  

  • 86. The oligosaccharide side chain on Asn-135 of alpha-antithrombin, absent in beta-antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change.
    Turk B; Brieditis I; Bock SC; Olson ST; Björk I
    Biochemistry; 1997 Jun; 36(22):6682-91. PubMed ID: 9184148
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Binding of antithrombin III and thrombin to immobilized heparin under flow conditions.
    Byun Y; Jacobs HA; Kim SW
    Biotechnol Prog; 1996; 12(2):217-25. PubMed ID: 8857192
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Mechanism of factor IXa inhibition by antithrombin in the presence of unfractionated and low molecular weight heparins and fucoidan.
    Mauray S; de Raucourt E; Talbot JC; Dachary-Prigent J; Jozefowicz M; Fischer AM
    Biochim Biophys Acta; 1998 Sep; 1387(1-2):184-94. PubMed ID: 9748565
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Effect of NaC1 on inactivation of bovine thrombin by antithrombin III in the presence of low affinity-heparin or dextran sulfate.
    Oshima G; Nagasawa K
    Thromb Res; 1986 Feb; 41(3):361-72. PubMed ID: 2422780
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Effect of heparin modification on its activity in enhancing the inhibition of thrombin by antithrombin III.
    Danishefsky I; Ahrens M; Klein S
    Biochim Biophys Acta; 1977 Jun; 498(1):215-22. PubMed ID: 560216
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Heparin sensitivity and resistance in the neonate: an explanation.
    Vieira A; Berry L; Ofosu F; Andrew M
    Thromb Res; 1991 Jul; 63(1):85-98. PubMed ID: 1658964
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Properties of antithrombin-thrombin complex formed in the presence and in the absence of heparin.
    Danielsson A; Björk I
    Biochem J; 1983 Aug; 213(2):345-53. PubMed ID: 6615439
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Antithrombin conformation and the catalytic role of heparin. I. Does cleavage by thrombin induce structural changes in the heparin-binding region of antithrombin?
    Peterson CB; Blackburn MN
    J Biol Chem; 1987 Jun; 262(16):7552-8. PubMed ID: 3584126
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparin.
    Olson ST; Swanson R; Raub-Segall E; Bedsted T; Sadri M; Petitou M; Hérault JP; Herbert JM; Björk I
    Thromb Haemost; 2004 Nov; 92(5):929-39. PubMed ID: 15543318
    [TBL] [Abstract][Full Text] [Related]  

  • 95. A disulfide bond in antithrombin is required for heparin-accelerated thrombin inactivation.
    Longas MO; Ferguson WS; Finlay TH
    J Biol Chem; 1980 Apr; 255(8):3436-41. PubMed ID: 7364749
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Anticoagulant properties of heparin preparations from different animal sources with equivalent high affinity for antithrombin III.
    Nagasawa K; Uchiyama H
    J Biochem; 1984 Mar; 95(3):619-26. PubMed ID: 6725227
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Clearance of thrombin from circulation in rabbits by high-affinity binding sites on endothelium. Possible role in the inactivation of thrombin by antithrombin III.
    Lollar P; Owen WG
    J Clin Invest; 1980 Dec; 66(6):1222-30. PubMed ID: 6255009
    [TBL] [Abstract][Full Text] [Related]  

  • 98. The consumption of antithrombin III during coagulation, its consequences for the calculation of prothrombinase activity and the standardisation of heparin activity.
    Béguin S; Kessels H; Dol F; Hemker HC
    Thromb Haemost; 1992 Aug; 68(2):136-42. PubMed ID: 1412157
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Selective disruption of heparin and antithrombin-mediated regulation of human factor IX.
    Westmark PR; Tanratana P; Sheehan JP
    J Thromb Haemost; 2015 Jun; 13(6):1053-63. PubMed ID: 25851619
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Interaction of S-protein of complement with thrombin and antithrombin III during coagulation. Protection of thrombin by S-protein from antithrombin III inactivation.
    Podack ER; Dahlbäck B; Griffin JH
    J Biol Chem; 1986 Jun; 261(16):7387-92. PubMed ID: 3754869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.